Business News

Blueprint Medicines and Roche Enter Cancer Immunotherapy Deal

CAMBRIDGE, Mass., March 15, 2016 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that it has entered into a worldwide collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, …

Read More »

Sarepta Announces FDA Advisory Committee Review Date for its DMD Drug Eteplirsen

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review Sarepta’s New Drug Application (NDA) for eteplirsen on April 25, 2016. The Prescription Drug User Fee …

Read More »

Dr. Reddy’s and TR-Pharm Announce Biosimilars Collaboration in Turkey

HYDERABAD, India–(BUSINESS WIRE)–Dr. Reddy’s and TR-Pharm announced today a strategic collaboration agreement involving 3 biosimilar products. A total of three products will be registered and subsequently commercialized as a part of this agreement by TR-Pharm in Turkey. TR-Pharm will also manufacture the drug substance and drug product upon completion of …

Read More »

MHA’s Business Summit Reveals Key Trends in the Alternate Site Health Care Industry

FLORHAM PARK, N.J., March 10, 2016 /PRNewswire/ —  Managed Health Care Associates, Inc. (MHA), a leading health care services and technology company focused on the alternate site health care provider marketplace, is pleased to announce the key industry trends that emerged from its 13th Annual Business Summit at The Bellagio, Las …

Read More »

Marathon Pharmaceuticals Announces Nationwide Expanded Access Program for DMD Patients

NORTHBROOK, Ill., March 9, 2016 /PRNewswire-USNewswire/ — Marathon Pharmaceuticals, a leader in developing treatments for rare diseases, announced today that it is expanding patient access to deflazacort, its investigational medicine for Duchenne Muscular Dystrophy (DMD). Through Marathon’s ACCESS DMD™ program, deflazacort is now being made available to qualified patients, at no cost, …

Read More »

Sanofi and Merck End Joint Vaccines Venture in Europe

KENILWORTH, N.J. & LYON, France–(BUSINESS WIRE)–Sanofi Pasteur and Merck, known as MSD outside the United States and Canada, today announced their intent to end their joint vaccines operations in Europe. Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage …

Read More »

Definiens Launches Immunoprofiling Panel to Rapidly Screen Tissue Samples for Immune Responses

MUNICH–(BUSINESS WIRE)–Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced the release of a new service, the Immunoprofiling Panel, to enable pharmaceutical companies, companion diagnostic developers and academic research centers working in immuno-oncology to quickly screen their target biomarkers and measure immune response. “Definiens leads …

Read More »

AbbVie Pays $595 Million for Rights to Boehringer Ingelheim’s Psoriasis Drug

NORTH CHICAGO, Ill. & INGELHEIM, Germany–(BUSINESS WIRE)–AbbVie (NYSE:ABBV) and Boehringer Ingelheim today announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis. AbbVie and Boehringer Ingelheim also are evaluating the potential of this biologic therapy in Crohn’s disease, psoriatic …

Read More »

Sorrento Therapeutics and Yuhan Form Joint Venture Company ImmuneOncia

SAN DIEGO and SEOUL, South Korea, March 2, 2016 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, and Yuhan Corporation (000100.KS; Yuhan), one of the largest and most respected pharmaceutical companies in South Korea, today announced …

Read More »

McKesson to Acquire Rexall Health for $2.23 Billion

SAN FRANCISCO and TORONTO – McKesson Corporation (NYSE: MCK), a leading international healthcare services and information technology company, and Katz Group, one of Canada’s largest privately-owned enterprises, today announced a definitive agreement to acquire Rexall Health from Katz Group for $3 billion CAD ($2.2 billion USD*, or approximately $1.9 billion USD* …

Read More »